TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31108869

Group type: EXPERIMENTAL
Intervention: Guided crockery set (sector plate, calibrated bowl, and calibrated glass)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Calibrated serving spoons (one for starch, one for protein, and one for vegetables)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both portion-control tools
Number of subjects: 29
Study: 28634173

Group type: EXPERIMENTAL
Intervention: Flutter device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lung Flute device
Number of subjects: 40
Study: 25459563

Group type: EXPERIMENTAL
Intervention: Six freeze-thaw cycles on sputum samples
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Three freeze-thaw cycles on sputum samples
Number of subjects: 8
Study: 24683770

Group type: EXPERIMENTAL
Intervention: Fluoride
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CPP-ACP with fluoride
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CPP-ACP with ozone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CPP-ACP without ozone
Number of subjects: 42
Study: 21206418

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 14 days
Number of subjects: 282

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg bid and amoxicillin 1 g bid for 7 days, followed by metronidazole 500 mg bid, tetracycline 500 mg qid, and lansoprazole 30 mg bid for an additional 7 days
Number of subjects: 282
Study: 19201400

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folic Acid (FA)
Number of subjects: 0
Study: 17460497

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12.5 mg zinc sulfate tablet daily for about 6 months)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 686
Study: 16305600

Group type: EXPERIMENTAL
Intervention: Low ATP1A1 subunit of the ATPase gene mRNA expression in CP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ATP1A1 subunit expression in Andeans in Lima
Number of subjects: 30

Group type: COMPARATOR
Intervention: Andean controls in Lima
Number of subjects: 30
Study: 11956122

Group type: EXPERIMENTAL
Intervention: Moxonidine SR 1.5 mg BID
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Moxonidine SR (0.3, 0.6, 0.9, 1.2, or 1.5 mg BID)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Moxonidine SR
Number of subjects: 268
Study: 9607349

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 95

Group type: COMPARATOR
Intervention: Staging model
Number of subjects: 95
Study: 8549952

Group type: EXPERIMENTAL
Intervention: Interferon alfa 2a (3 million units, three times a week for 52 weeks)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Interferon alfa 2a (3 million units, three times a week for 8 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 70
Study: 2194987

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine 100 mg
Number of subjects: 0
Study: 486862

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noise during learning
Number of subjects: 0
Study: 31693078

Group type: EXPERIMENTAL
Intervention: 1 month of dual antiplatelet therapy (DAPT) followed by 23 months of ticagrelor monotherapy
Number of subjects: 15991

Group type: COMPARATOR
Intervention: 12 months of DAPT followed by 12 months of aspirin monotherapy
Number of subjects: 15991

Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 15991
Study: 31661439

Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA) with 1470 nm diode laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency Ablation (RFA) with bipolar Radiofrequency Induced Thermotherapy
Number of subjects: 50
Study: 28577272

Group type: EXPERIMENTAL
Intervention: ADV6209 (15 mg, oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Midazolam hydrochloride intravenous solution (5 mg, i.v.)
Number of subjects: 12
Study: 25813411

Group type: EXPERIMENTAL
Intervention: Thrice-daily (TID) U‐500R insulin
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Twice-daily (BID) U‐500R insulin
Number of subjects: 325
Study: 23816977

Group type: EXPERIMENTAL
Intervention: Topical application of 20% hydroxypropyl‐β‐cyclodextrin (2‐HPβCD) in a polyethylene glycol (PEG) formulation, applied twice daily for 6 months.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle control (PEG formulation without 2‐HPβCD), applied twice daily for 6 months.
Number of subjects: 40
Study: 21999413

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Carvedilol, Metoprolol tartrate, Metoprolol succinate
Number of subjects: 27
Study: 19589851

Group type: EXPERIMENTAL
Intervention: Physical therapist-directed exercise counseling plus fitness center-based exercise training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Laboratory-based, supervised exercise
Number of subjects: 24
Study: 16492824

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg sublingually 2 hours before surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: Piroxicam 40 mg sublingually 10 minutes after surgery (Control)
Number of subjects: 52
Study: 15075512

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 200/100 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400/100 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400/200 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) open-label 400/100 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 100
Study: 11297963

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contemporary conventional care
Number of subjects: 0
Study: 9007492

Group type: EXPERIMENTAL
Intervention: Dexamethasone (systemic group) for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Budesonide (inhaled group, 100 micrograms qds) for 10 days
Number of subjects: 40
Study: 8373274

Group type: EXPERIMENTAL
Intervention: Polymyxin B intravenously for 1 week postburn
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 76
Study: 3115153

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg . kg‐1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Propofol with Alfentanil (2 mg . kg‐1 propofol with 4 micrograms . kg‐1 alfentanil)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ketamine with Midazolam (0.5 mg . kg‐1 ketamine with 0.25 mg . kg‐1 midazolam)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ketamine with Midazolam (1 mg . kg‐1 ketamine with 0.1 mg . kg‐1 midazolam)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Propofol groups
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ketamine-Midazolam groups
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 200
Study: 29685017

Group type: EXPERIMENTAL
Intervention: Posterior hemivertebra resection in combination with screw rod internal fixation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Posterior hemivertebra resection only
Number of subjects: 115
Study: 27010115

Group type: EXPERIMENTAL
Intervention: PPS 100 mg thrice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PPS 100 mg once daily and placebo twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (vitamin B complex tablet) thrice daily
Number of subjects: 32
Study: 24532969

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23336539

Group type: EXPERIMENTAL
Intervention: Stress group (Trier Social Stress Test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-stress control group
Number of subjects: 0
Study: 21515737

Group type: EXPERIMENTAL
Intervention: Induced disbelief in free will
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 19064024

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1832
Study: 16503687

Group type: EXPERIMENTAL
Intervention: Wrist and forearm training (Group 2)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Full-body resistance exercises (Group 1)
Number of subjects: 43
Study: 12949433

Group type: EXPERIMENTAL
Intervention: Music during endoscopy
Number of subjects: 301

Group type: COMPARATOR
Intervention: No music during endoscopy
Number of subjects: 301
Study: 10870071

Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg/day orally for 4 days) after 3 days of intravenous ceftriaxone (100 mg/kg/day) and amikacin (15 mg/kg/day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Ceftriaxone plus amikacin (for 7 days)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study: 9100553

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH; mean dose 2.4 IU daily)
Number of subjects: 20
Study: 8096959

Group type: EXPERIMENTAL
Intervention: halofantrine (72 mg/kg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: halofantrine (24 mg/kg, 3 doses)
Number of subjects: 114

Group type: COMPARATOR
Intervention: mefloquine (25 mg/kg)
Number of subjects: 114
Study: 3589701

Group type: EXPERIMENTAL
Intervention: alfa‐2b interferon (Intron A, Schering Corp, Kenilworth, NJ), 2 megaunits/m2, subcutaneously, three times a week
Number of subjects: 128

Group type: COMPARATOR
Intervention: observation only
Number of subjects: 128

Group type: COMPARATOR
Intervention: continued interferon therapy
Number of subjects: 128
Study: 30268528

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg/h)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 27376698

Group type: EXPERIMENTAL
Intervention: EX (exercise followed by no meal)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EX-LGI (exercise followed by a meal with low-glycemic index carbohydrates)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EX-HGI (exercise followed by a meal with high-glycemic index carbohydrates)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no exercise or meal)
Number of subjects: 23
Study: 24679891

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 23750690

Group type: EXPERIMENTAL
Intervention: Light intensity aerobic exercise
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Vigorous intensity aerobic exercise
Number of subjects: 162

Group type: COMPARATOR
Intervention: Passive control condition
Number of subjects: 162
Study: 20609631

Group type: EXPERIMENTAL
Intervention: PEARLS intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 19060427

Group type: EXPERIMENTAL
Intervention: Allicor (600 mg daily)
Number of subjects: 42
Study: 17135784

Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride immediate release (IR) 15 mg twice daily
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride extended release (ER) 30 mg once daily
Number of subjects: 988

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 988
Study: 12698385

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 0
Study: 10493704

Group type: EXPERIMENTAL
Intervention: Structured educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 8530597

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1936474

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40
Study: 7317248

Group type: EXPERIMENTAL
Intervention: guanethidine 10mg i.v.
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 31162005

Group type: COMPARATOR
Intervention: Cholera vaccine only
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Vaccine plus behavior change (cholera vaccine and handwashing plus drinking water chlorination promotion)
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Vaccine plus behavior change
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Vaccine only
Number of subjects: 60000
Study: 28515547

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Simple Advice (SA)
Number of subjects: 100
Study: 25753159

Group type: EXPERIMENTAL
Intervention: New treatment protocol for gestational diabetes
Number of subjects: 189

Group type: COMPARATOR
Intervention: Regular method of treatment for gestational diabetes
Number of subjects: 189
Study: 23797281

Group type: EXPERIMENTAL
Intervention: Polysubstance use (PSU)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Alcohol dependence (ALC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Light drinking controls (CON)
Number of subjects: 3
Study: 20660131

Group type: EXPERIMENTAL
Intervention: 38 per cent phosphoric acid gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 9.6 per cent hydrofluoric acid gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Airborne aluminium trioxide particle abrasion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate particle abrasion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diamond bur
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control with no surface treatment
Number of subjects: 90
Study: 19401377

Group type: COMPARATOR
Intervention: rhIGF‐I (40 microg/kg per 12h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: rhGH + rhIGF‐I (50 microg/kg/d)
Number of subjects: 8
Study: 16890068

Group type: EXPERIMENTAL
Intervention: Fresh reconstituted botulinum toxin type A (BTX‐A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Frozen reconstituted botulinum toxin type A (BTX‐A)
Number of subjects: 43
Study: 15615275

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 227
Study: 11465967

Group type: COMPARATOR
Intervention: Rauwolfia derivatives
Number of subjects: 1585

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 1585

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1585

Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 1585

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 1585

Group type: COMPARATOR
Intervention: Longitudinal studies (additional five studies)
Number of subjects: 1585
Study: 9213276

Group type: EXPERIMENTAL
Intervention: Thigh-high sequential pneumatic compression wraps
Number of subjects: 136

Group type: COMPARATOR
Intervention: Pneumatic foot-compression wraps
Number of subjects: 136
Study: 8424297

Group type: EXPERIMENTAL
Intervention: Combined thoracic epidural anaesthesia/light general anaesthesia with continuous epidural bupivacaine 10 mg.h‐1 and morphine 0.2 mg.h‐1 for 38 h after surgery plus systemic ibuprofen 600 mg x 8 h‐1
Number of subjects: 31

Group type: COMPARATOR
Intervention: General anaesthesia and postoperative analgesia with systemic morphine and ibuprofen 600 mg x 8 h‐1
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined thoracic epidural anaesthesia/light general anaesthesia
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study: 3117467

Group type: EXPERIMENTAL
Intervention: Nitroglycerin-TTS 5 mg/24 h
Number of subjects: 99

Group type: COMPARATOR
Intervention: Long-acting nitroglycerin tablets, 10.4 mg daily
Number of subjects: 99
Study: 31910658

Group type: EXPERIMENTAL
Intervention: DSR solution (sodium-free 10% dextrose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard PD solution (Dianeal 4.25% dextrose)
Number of subjects: 0
Study: 30120404

Group type: EXPERIMENTAL
Intervention: DHA-CHO-VE treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FADS1 mRNA level
Number of subjects: 0
Study: 27621162

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg controlled release twice a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 32
Study: 25640891

Group type: EXPERIMENTAL
Intervention: rhC1INH 50 IU/kg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups (rhC1INH and saline)
Number of subjects: 74
Study: 23944684

Group type: EXPERIMENTAL
Intervention: High-caloric food supplement with high fat content
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-caloric food supplement with high carbohydrate content
Number of subjects: 26
Study: 21052890

Group type: EXPERIMENTAL
Intervention: WIF-1 expression
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: WIF-1 methylation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: WIF-1 methylation and expression correlation
Number of subjects: 105
Study: 19082800

Group type: EXPERIMENTAL
Intervention: Shengmai injection (SMI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 120
Study: 16562692

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional invasive synchronized intermittent mandatory ventilation (SIMV) plus pressure support ventilation (PSV)
Number of subjects: 76
Study: 12821964

Group type: EXPERIMENTAL
Intervention: Intensive diet therapy (6000-7000 kJ/day or 1400-1700 kcal/day) with weekly dietitian contact for 12 weeks
Number of subjects: 51
Study: 10364866

Group type: EXPERIMENTAL
Intervention: Ketamine 2.5 mg.kg‐1
Number of subjects: 32

Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 32
Study: 8894146

Group type: EXPERIMENTAL
Intervention: 1.25 mg/day tibolone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day tibolone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 1825097

Group type: EXPERIMENTAL
Intervention: Intravenous captopril
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 6301671

Group type: EXPERIMENTAL
Intervention: Adriamycin (doxorubicin) 50 mg/m2 IV every three weeks
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Adriamycin (doxorubicin) 75 mg/m2 IV every three weeks
Number of subjects: 599

Group type: COMPARATOR
Intervention: Cytoxan (cyclophosphamide)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Adriamycin plus Cytoxan
Number of subjects: 599
Study: 31454851

Group type: EXPERIMENTAL
Intervention: Pharmacological prophylaxis plus pancreatic duct stenting (group A)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Pharmacological prophylaxis alone (group B)
Number of subjects: 414
Study: 29656914

Group type: EXPERIMENTAL
Intervention: Safety in Seconds v2.0TM mobile app
Number of subjects: 742
Study: 26559482

Group type: EXPERIMENTAL
Intervention: Topical imiquimod-cream followed by intradermal trivalent influenza vaccine (INF-Q-ID)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Topical aqueous-cream control followed by intradermal trivalent influenza vaccine (INF-C-ID)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Topical aqueous-cream control followed by intramuscular trivalent influenza vaccine (INF-C-IM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Topical imiquimod-cream followed by intradermal normal-saline injection (SAL-Q-ID)
Number of subjects: 160
Study: 24190691

Group type: EXPERIMENTAL
Intervention: Incredible Years parent-training group (10-week program)
Number of subjects: 273
Study: 22611089

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Solution-focused therapy (SFT)
Number of subjects: 198
Study: 19596446

Group type: EXPERIMENTAL
Intervention: Antenatal psycho-educational intervention
Number of subjects: 377

Group type: COMPARATOR
Intervention: Usual care condition (control)
Number of subjects: 377
Study: 18519821

Group type: EXPERIMENTAL
Intervention: Early detection (ED) system implemented in one health care area
Number of subjects: 231

Group type: COMPARATOR
Intervention: No early detection (no-ED) area
Number of subjects: 231
Study: 15815777

Group type: EXPERIMENTAL
Intervention: Surgical closure of ASD
Number of subjects: 91

Group type: COMPARATOR
Intervention: Transcatheter closure of ASD (Amplatzer occluder)
Number of subjects: 91
Study: 12094862

Group type: EXPERIMENTAL
Intervention: 60‐100 mg/day prednisolone equivalent, tapered to 10‐15 mg/day within 6 weeks and maintained for another 4 weeks
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Steroid resistant patients
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Initial CDAI in resistant patients
Number of subjects: 300
Study: 9685127

Group type: EXPERIMENTAL
Intervention: Dextran 40 infusion for 72 hours after surgery
Number of subjects: 244

Group type: COMPARATOR
Intervention: No dextran 40 infusion
Number of subjects: 244
Study: 8600180

Group type: EXPERIMENTAL
Intervention: Intravenous pilocarpine (P)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 2782505

Group type: EXPERIMENTAL
Intervention: Social influences curriculum in program schools (six core and two maintenance sessions in grade 6, two booster sessions in grade 7, and one booster session in grade 8)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Students who had left school
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Grade 6 smoking experience and social risk
Number of subjects: 22
Study: 4430473

Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 6
Study: 29516305

Group type: EXPERIMENTAL
Intervention: Light-emitting diode therapy (LEDT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8